THE ENCLOSED SLIDES ARE FREE FOR PUBLIC USE DECEMBER 2015 ACHP Drug Cost Chart Pack

The Spike in Drug Costs Advancements in pharmaceuticals can result in drugs that offer fewer side effects, improve a patient’s quality of life and save lives, but what if not everyone can afford them? THERE’S ENORMOUS PRESSURE ON….. Consumers and their families, who may be faced with the difficult choice between paying for MS medications and other necessities. Employers, who may be forced to make cuts to their overall benefits package in order to fund rising health care costs. Health care providers, who treat an increase in disease-related complications due in part to non-adherence to costly medications. Health plans and other payers, who want to ensure people get the right drugs and keep coverage affordable. Federal government, which is bearing an ever-growing share of the costs of these drugs, placing increasing pressure on the federal budget.

The Spike in Drug Costs: Diabetes GENERAL STATISTICS: 1 in 11 people in the U.S. has diagnosed or undiagnosed diabetes. This is expected to increase to 1 in 3 people by The cost of diagnosed diabetes in 2012 was $245 billion.

The Spike in Drug Costs: Diabetes Primarily because of escalating drug costs, spending on insulin and other diabetes medications is expected to rise 18.3 percent over the next three years, a rate of increase 60 times greater than the recent income growth average of just 0.3 percent across all households.

The Spike in Drug Costs: Diabetes Diabetes Drugs with Significant Percent Price Changes Over Five Years (3/1/2010 – 2/28/2015) Source: Medi-Span® Price Rx®. Figures reflect wholesale acquisition cost. Note: Price modifications will alter the values reflected above.

The Spike in Drug Costs: Multiple Sclerosis GENERAL STATISTICS: Multiple Sclerosis (MS) affects at least 400,000 people in the United States and more than 2.5 million globally. MS drugs help people manage their condition and enhance their comfort and quality of life. The cost of taking MS drugs can span a lifetime. There is currently no cure for MS.

The Spike in Drug Costs: Multiple Sclerosis Lemtrada, approved for sale in the U.S. in 2014, has a two-year course of treatment estimated at $158,000.

The Spike in Drug Costs: Multiple Sclerosis 8 MS Drugs with the Highest % Price Changes Since Launch for a 30-Day Supply *Date listed is the first instance of available pricing data in Medi-Span® Price Rx®. The true launch date is earlier than that listed. Source: Medi-Span® Price Rx® and Figures reflect wholesale acquisition cost. Note: Price modifications will alter the values reflected above.

The Spike in Drug Costs: Multiple Sclerosis First-generation MS drugs, originally costing $8,000 - $11,000 per year, can now exceed $60,000 per person per year.

The Spike in Drug Costs: Multiple Sclerosis

The new 40 mg dose of the widely prescribed drug Copaxone costs $5,008 a month, yet shows no gain in efficacy over the 20 mg dose.

The Spike in Drug Costs: Rheumatoid Arthritis About 1.3 million Americans have rheumatoid arthritis (RA) and this number is forecast to reach 1.68 million by GENERAL STATISTICS:

The Spike in Drug Costs: Rheumatoid Arthritis The cost of taking RA drugs can exceed $1 million over the course of an individual’s lifetime.

The Spike in Drug Costs: Rheumatoid Arthritis Sixty percent of people with inadequately treated RA are unable to work 10 years after onset.

The Spike in Drug Costs: Rheumatoid Arthritis RA Drug Prices for 30-Day Supply,

The Spike in Drug Costs: Rheumatoid Arthritis The cost of treating RA in the U.S. will increase from $6.4 billion in 2013 to $9.3 billion by 2020.